Study title: Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J et al. A controlled trial comparing foscarnet with vidarabine for acyclovir- resistant mucocutaneous herpes-simplex in the acquired- immunodeficiencysyndrome. New-England-Journalof- Medicine 325 (8): 551-555.Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J et al. A controlled trial comparing foscarnet with vidarabine for acyclovir- resistant mucocutaneous herpes-simplex in the acquired- immunodeficiencysyndrome. New-England-Journalof- Medicine 325 (8): 551-555.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Virus Diseases [C02] | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: Foscarnet | |||||
| ATC code: | |||||
| Document link: Safrin S et al 1991.pdf | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Review Article | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |